Todd Hembrough
Durham VA Medical Center(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS(2017)552 cited
- → Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial(2018)551 cited
- → Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade(2020)327 cited
- → Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition(2018)271 cited
- Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.(2003)
- → Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study(2019)194 cited
- → Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation(2006)192 cited
- → An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer(2017)175 cited
- → EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer(2018)143 cited
- → ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action(2010)128 cited